AstraZeneca PLC (NAS:AZN)

$ 69.57 +0.020 (+0.03%) Market Cap: 213.83 Bil Enterprise Value: 239.42 Bil PE Ratio: 29.51 PB Ratio: 5.00 GF Score: 87/100

Q4 2024 AstraZeneca PLC Earnings Call Transcript

Feb 06, 2025 / 11:00AM GMT

Release Date Price: $72.36 (+2.01%)

Transcript

Key Points

Positve

AstraZeneca PLC (AZN) reported a strong financial performance in 2024, with total revenue up 21% and core EPS up 19%, indicating robust company momentum.
The company achieved significant pipeline advancements, with nine high-value pivotal trials representing over $5 billion in non-risk-adjusted peak revenue.
AstraZeneca PLC (AZN) has eight new medicines approved to date, including the recent approval of Datroway, contributing to its goal of 20 new medicines by 2030.
The company experienced strong growth across all therapy areas and key geographies, with emerging markets showing a 22% growth in 2024.
AstraZeneca PLC (AZN) anticipates a catalyst-rich period in 2025, with high-value trial readouts expected for several existing medicines and new molecular entities (NMEs).

Negative

AstraZeneca PLC (AZN) is facing ongoing investigations in China regarding suspected unpaid importation taxes, which could result in significant fines.
The company experienced a 3% decline in Q4 2024 China revenues, primarily due to year-end hospital ordering dynamics and lower demand for respiratory products.
AstraZeneca PLC (AZN) anticipates headwinds in 2025 from the inclusion of several medicines in China's Volume-Based Procurement (VBP) program, impacting revenue.
The company expects a 60 to 70 basis points decline in product sales gross margin in 2025 due to factors like the Inflation Reduction Act (IRA) in the US and VBP in China.
AstraZeneca PLC (AZN) faces challenges in gaining market access for new products like Airsupra, which has seen slower-than-expected uptake due to access issues.

Operator

Good morning to those joining from the UK and the US. Good afternoon to those in Central Europe, and good evening to those listening in Asia. Welcome, ladies and gentlemen, to AstraZeneca's full year and Q4 2024 results conference call for investors and analysts.

Before I hand over to AstraZeneca, I'd like to read the safe harbor statement. The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.

Any forward-looking statements made on this call reflect the knowledge and information available at the time of this call. The company undertakes no obligation to update forward-looking

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.